Log In Get Started
Press Releases April 21, 2026 04:05 PM

Getty Realty Corp. Announces Regular Quarterly Cash Dividend

Getty Realty Corp. Declares Quarterly Cash Dividend of $0.485 per Share

By Ajmal Hussain
Share
Twitter Reddit Facebook LinkedIn
GTY

Getty Realty Corp., a net lease REIT specializing in convenience and automotive retail real estate, announced a cash dividend of $0.485 per common share payable July 9, 2026, to shareholders of record as of June 25, 2026. The company’s portfolio comprises 1,174 properties across 44 U.S. states and Washington, D.C.

Getty Realty Corp. Announces Regular Quarterly Cash Dividend
GTY
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Getty Realty Corp. focuses on net lease real estate in convenience and automotive retail sectors.
  • The company declared a quarterly cash dividend of $0.485 per share, maintaining shareholder returns.
  • Its expansive portfolio includes 1,174 single tenant retail properties across most U.S. states and Washington, D.C.

NEW YORK, April 21, 2026 (GLOBE NEWSWIRE) -- Getty Realty Corp. (NYSE: GTY) (“Getty” or the “Company”), a net lease REIT focused on convenience and automotive retail real estate, announced today that its Board of Directors declared a cash dividend of $0.485 per common share payable on July 9, 2026 to holders of record on June 25, 2026.

About Getty Realty Corp.

Getty Realty Corp. is a publicly traded, net lease REIT specializing in the acquisition, financing and development of convenience, automotive and other single tenant retail real estate. As of December 31, 2025, the Company’s portfolio included 1,174 freestanding properties located in 44 states across the United States and Washington, D.C.

Contact:        
Investor Relations
(646) 349-0598
[email protected] 


Risks

  • Dividend payments depend on the company’s financial performance and market conditions impacting real estate sectors.
  • Exposure to retail and automotive real estate markets subjects the company to economic fluctuations and sector-specific risks.
  • Geographic concentration in the U.S. means changes in U.S. federal or state regulations could impact operations.

More from Press Releases

Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026 Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026 Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 Jun 12, 2026 ROMA Green Finance Establishes Dedicated Artificial Intelligence and High-Performance Computing Infrastructure Investment Vertical Jun 12, 2026